MA40880A - Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus - Google Patents

Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus

Info

Publication number
MA40880A
MA40880A MA040880A MA40880A MA40880A MA 40880 A MA40880 A MA 40880A MA 040880 A MA040880 A MA 040880A MA 40880 A MA40880 A MA 40880A MA 40880 A MA40880 A MA 40880A
Authority
MA
Morocco
Prior art keywords
polyomaviruses
eradication
rna
virus
guided
Prior art date
Application number
MA040880A
Other languages
English (en)
Inventor
Wenhui Hu
Kamel Khalili
Hassen Wollebo
Original Assignee
Temple Univ Of The Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ Of The Commonwealth filed Critical Temple Univ Of The Commonwealth
Publication of MA40880A publication Critical patent/MA40880A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
MA040880A 2014-10-30 2015-10-29 Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus MA40880A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072927P 2014-10-30 2014-10-30
US201562169390P 2015-06-01 2015-06-01
US201562169638P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
MA40880A true MA40880A (fr) 2017-09-05

Family

ID=55858408

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040880A MA40880A (fr) 2014-10-30 2015-10-29 Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus

Country Status (11)

Country Link
US (2) US20170333572A1 (fr)
EP (1) EP3212795A4 (fr)
CN (2) CN115044570A (fr)
AU (1) AU2015338993B2 (fr)
CA (1) CA2967990C (fr)
HK (1) HK1247636A1 (fr)
MA (1) MA40880A (fr)
MX (1) MX2017005672A (fr)
RU (1) RU2747722C2 (fr)
WO (1) WO2016070070A1 (fr)
ZA (1) ZA201703163B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (fr) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
EP2841572B1 (fr) 2012-04-27 2019-06-19 Duke University Correction génétique de gènes ayant subi une mutation
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3362571A4 (fr) 2015-10-13 2019-07-10 Duke University Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
AU2016366229A1 (en) * 2015-12-09 2018-05-17 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
JP2019512458A (ja) * 2016-01-25 2019-05-16 エクシジョン バイオセラピューティクス インコーポレイテッド Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
US20190161743A1 (en) * 2016-05-09 2019-05-30 President And Fellows Of Harvard College Self-Targeting Guide RNAs in CRISPR System
RU2018144745A (ru) * 2016-06-01 2020-07-09 Эксижн Биотерапьютикс, Инк. Композиции и способы лечения, направленные на литические и лизогенные вирусы
EP3487523B1 (fr) * 2016-07-19 2023-09-06 Duke University Applications thérapeutiques de l'édition du génome fondée sur cpf1
EP3494215A1 (fr) 2016-08-03 2019-06-12 President and Fellows of Harvard College Éditeurs de nucléobases d'adénosine et utilisations associées
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
WO2018071868A1 (fr) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Administration d'aav d'éditeurs de nucléobases
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
WO2018165504A1 (fr) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression de la douleur par édition de gène
WO2018165629A1 (fr) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Éditeur de base cytosine à guanine
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
SG11202109882VA (en) 2019-03-19 2021-10-28 Broad Inst Inc Methods and compositions for editing nucleotide sequences
WO2021096912A2 (fr) * 2019-11-11 2021-05-20 Temple University - Of The Commonwealth System Of Higher Education Système crispr/cas9 en tant qu'agent d'inhibition d'une infection par le polyome jc
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
CN112322587A (zh) * 2020-09-17 2021-02-05 杭州市第一人民医院 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用
RU2747819C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ получения препарата рибонуклеопротеинового комплекса CRISPR/Cas и препарат для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях
RU2747820C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Система CRISPR-Cas для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP2013222B1 (fr) * 2006-04-28 2013-02-13 Alnylam Pharmaceuticals Inc. Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
WO2014113493A1 (fr) * 2013-01-16 2014-07-24 Emory University Complexes d'acide nucléique cas9 et leurs utilisations

Also Published As

Publication number Publication date
MX2017005672A (es) 2018-11-09
ZA201703163B (en) 2019-03-27
RU2747722C2 (ru) 2021-05-13
WO2016070070A1 (fr) 2016-05-06
CN115044570A (zh) 2022-09-13
EP3212795A4 (fr) 2018-06-27
EP3212795A1 (fr) 2017-09-06
AU2015338993B2 (en) 2021-12-09
CN107406854A (zh) 2017-11-28
HK1247636A1 (zh) 2018-09-28
CA2967990A1 (fr) 2016-05-06
CN107406854B (zh) 2022-03-11
AU2015338993A1 (en) 2017-05-25
CA2967990C (fr) 2024-02-13
US20170333572A1 (en) 2017-11-23
RU2017115838A (ru) 2018-11-30
US20230001016A1 (en) 2023-01-05
RU2017115838A3 (fr) 2018-11-30

Similar Documents

Publication Publication Date Title
MA40880A (fr) Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
EP3408392A4 (fr) Éradication du virus jc humain et d'autres polyomavirus guidée par un arn
MA50813A (fr) Vaccins contre le virus d'epstein-barr
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
HK1223628A1 (zh) β- 新的 -酮- β-烷基膽烷酸衍生物在製備奧貝膽酸以及其在醫藥領域的用途
MA41349A (fr) Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
IL256515A (en) Therapeutic peptides and methods of use thereof
EP3220953A4 (fr) Compositions et procédés d'utilisation de peptides thérapeutiques en relation avec p53 et de leurs analogues
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3419638A4 (fr) Compositions et procédés de traitement de maladies infectieuses chroniques
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
HK1205147A1 (en) Truncated l1 proteins of human papillomavirus type 45 45 l1
EP3265108A4 (fr) Peptides et compositions les comprenant, et utilisations de ces derniers dans le traitement de maladies
HUE063656T2 (hu) Pegilált liposzómák és véralvadási faktorok gyógyszerészeti formulációi
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
ZA201805989B (en) Compositions and methods of treatment of chronic infectious diseases
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
TH1501007357A (th) โครงสร้างเนื้อเยื่อและวิธีการเตรียมของมัน
GB201401297D0 (en) Bernard's theory of agriculture in application and in design of concept